E9-24881. New Animal Drugs; Change of Sponsor; Sometribove Zinc Suspension  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for sometribove zinc suspension from Monsanto Co. to Elanco Animal Health, A Division of Eli Lilly & Co.

    DATES:

    This rule is effective October 16, 2009.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8307, e-mail: david.newkirk@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Monsanto Co., 800 North Lindbergh Blvd., St. Louis, MO 63167, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 140-872 for POSILAC (sometribove zinc suspension) to Elanco Animal Health, A Division of Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285. Accordingly, the regulations are amended in 21 CFR 522.2112 to reflect this change of sponsorship.

    Following this change of sponsorship, Monsanto Co. is no longer the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for Monsanto Co.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects

    21 CFR Part 510

    • Administrative practice and procedure
    • Animal drugs
    • Labeling
    • Reporting and recordkeeping requirements

    21 CFR Part 522

    • Animal drugs
    End List of Subjects Start Amendment Part

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

    End Amendment Part Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority Start Amendment Part

    2. In § 510.600, in the table in paragraph (c)(1) remove the entry for “Monsanto Co.”; and in the table in paragraph (c)(2) remove the entry for “000911”.

    End Amendment Part Start Part

    PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    3. The authority citation for 21 CFR part 522 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority
    [Amended]
    Start Amendment Part

    4. In paragraph (b) of § 522.2112, remove “000911” and add in its place “000986”.

    End Amendment Part Start Signature

    Dated: October 9, 2009.

    Bernadette Dunham,

    Director, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. E9-24881 Filed 10-15-09; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Comments Received:
0 Comments
Effective Date:
10/16/2009
Published:
10/16/2009
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
E9-24881
Dates:
This rule is effective October 16, 2009.
Pages:
53164-53164 (1 pages)
Docket Numbers:
Docket No. FDA-2009-N-0665
Topics:
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements
PDF File:
e9-24881.pdf
CFR: (1)
21 CFR 522.2112